Home > Search Results: Jayadeva, G.
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 1 records in 0.02 seconds.
Articles, 1 records found
Articles 1 records found  
1.
10 p, 476.1 KB Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors / Le Tourneau, C. (Paris-Saclay University) ; Becker, H. (University of Freiburg) ; Claus, R. (Medical Faculty Augsburg University) ; Elez, Elena (Vall d'Hebron Institut d'Oncologia) ; Ricci, F. (Paris-Saclay University) ; Fritsch, R. (University of Freiburg) ; Silber, Y. (Medical Faculty Augsburg University) ; Hennequin, A. (Centre Georges-François Leclerc) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Jayadeva, G. (Boehringer Ingelheim International GmbH) ; Luedtke, D. (Boehringer Ingelheim Pharma GmbH and Co KG) ; He, M. (Boehringer Ingelheim Pharmaceuticals Inc.) ; Isambert, N. (Centre Georges-François Leclerc) ; Universitat Autònoma de Barcelona
BI 836880 is a humanized bispecific nanobody® that inhibits vascular endothelial growth factor and angiopoietin-2. Here, we report results from two phase I, nonrandomized, dose-escalation studies (NCT02674152 and NCT02689505; funded by Boehringer Ingelheim) evaluating BI 836880 in patients with confirmed locally advanced or metastatic solid tumors, refractory to standard therapy, or for which standard therapy was ineffective. [...]
2022 - 10.1016/j.esmoop.2022.100576
ESMO open, Vol. 7 (september 2022)  
Detailed record - Creative Commons

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with